Vidal V, Roussin R, Leguerrier A, Rioux C, Logeais Y
Clinique chirurgicale cardiovasculaire et thoracique, hôpital de Pontchaillou, Rennes.
Arch Mal Coeur Vaiss. 1993 Jan;86(1):35-40.
Between 1980 and 1985, 239 patients underwent mitral valve replacement with a Saint Jude Medical (130) or Carpentier-Edwards (109) prosthesis alone or associated with correction of tricuspid regurgitation. Age, NYHA grade and pulmonary artery pressures were comparable in the two groups. Two hundred and seventeen of the 221 survivors were contacted (98.6% follow-up): the long-term prosthesis-related mortality was 35% in the Saint Jude Medical group and 22.5% in the Carpentier-Edwards group. The global survival at 9 years was 82% in the Saint Jude Medical group but only 63% in the Carpentier-Edwards group. The actuarial thromboembolic-free rate at 9 years was 96% in the Saint Jude Medical and 86% in the Carpentier-Edwards group (not significant). Two Saint Jude Medical and one Carpentier-Edwards bioprosthesis thrombosed--a linear rate of 0.2% PY and 0.1% PY respectively. Furthermore, there was no significant difference in the actuarial rate of haemorrhagic complications between the two groups. Endocarditis and valve degeneration were more common in the Carpentier-Edwards group (1.3% and 1.6% PY respectively). Over the 9 year period, the thromboembolic complications of the Saint Jude Medical and Carpentier-Edwards prostheses were similar in actuarial and linear terms. With respect to long-term mortality and morbidity, the results with the Saint Jude Medical valve seem to be superior to those of the Carpentier-Edwards bioprosthesis.
1980年至1985年间，239例患者接受了单独使用圣犹达医疗公司（130例）或卡朋蒂埃 - 爱德华兹（109例）人工瓣膜的二尖瓣置换术，或同时进行三尖瓣反流矫正术。两组患者的年龄、纽约心脏协会（NYHA）分级和肺动脉压力相当。在221名幸存者中，有217名（随访率98.6%）被联系到：圣犹达医疗组与人工瓣膜相关的长期死亡率为35%，卡朋蒂埃 - 爱德华兹组为22.5%。圣犹达医疗组9年的总体生存率为82%，而卡朋蒂埃 - 爱德华兹组仅为63%。圣犹达医疗组9年的无血栓栓塞率为96%，卡朋蒂埃 - 爱德华兹组为86%（无显著差异）。两枚圣犹达医疗和一枚卡朋蒂埃 - 爱德华兹生物瓣膜发生血栓形成，线性发生率分别为每年0.2%和每年0.1%。此外，两组出血并发症的精算发生率无显著差异。心内膜炎和瓣膜退变在卡朋蒂埃 - 爱德华兹组更为常见（分别为每年1.3%和每年1.6%）。在9年期间，圣犹达医疗和卡朋蒂埃 - 爱德华兹人工瓣膜的血栓栓塞并发症在精算和线性方面相似。就长期死亡率和发病率而言，圣犹达医疗瓣膜的结果似乎优于卡朋蒂埃 - 爱德华兹生物瓣膜。
